Date published: 2026-3-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

Palbociclib (CAS 571190-30-2)

0.0(0)
Write a reviewAsk a question

Datasheets
Alternate Names:
PD-0332991 Ibrance PD0332991 PD 0332991
CAS Number:
571190-30-2
Molecular Weight:
447.53
Molecular Formula:
C24H29N7O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

QUICK LINKS


Palbociclib (CAS 571190-30-2) References

  1. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.  |  Finn, RS., et al. 2015. Lancet Oncol. 16: 25-35. PMID: 25524798
  2. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.  |  Cristofanilli, M., et al. 2016. Lancet Oncol. 17: 425-439. PMID: 26947331
  3. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.  |  Bollard, J., et al. 2017. Gut. 66: 1286-1296. PMID: 27849562
  4. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.  |  Chen, F., et al. 2018. Anticancer Agents Med Chem. 18: 1241-1251. PMID: 28403773
  5. Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature.  |  Beddok, A., et al. 2020. Br J Cancer. 123: 905-908. PMID: 32595213
  6. Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.  |  Groenland, SL., et al. 2020. Clin Pharmacokinet. 59: 1501-1520. PMID: 33029704
  7. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.  |  Mayer, EL., et al. 2021. Lancet Oncol. 22: 212-222. PMID: 33460574
  8. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.  |  Xu, B., et al. 2022. Eur J Cancer. 175: 236-245. PMID: 36155117
  9. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.  |  Bidard, FC., et al. 2022. Lancet Oncol. 23: 1367-1377. PMID: 36183733
  10. Palbociclib blocks neutrophilic phosphatidylinositol 3-kinase activity to alleviate psoriasiform dermatitis.  |  Chen, PJ., et al. 2023. Br J Pharmacol. 180: 2172-2188. PMID: 36967633

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Palbociclib, 50 mg

sc-507366
50 mg
$321.00